Corcept Therapeutics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2183521028
USD
41.30
4.99 (13.74%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Apellis Pharmaceuticals, Inc.
Amicus Therapeutics, Inc.
ACADIA Pharmaceuticals, Inc.
Perrigo Co. Plc
Prestige Consumer Healthcare, Inc.
Organon & Co.
Corcept Therapeutics, Inc.
Insmed, Inc.
Cerevel Therapeutics Holdings, Inc.
MoonLake Immunotherapeutics
Bausch Health Cos., Inc.

Why is Corcept Therapeutics, Inc. ?

1
Negative results in Jun 25
  • CASH AND EQV(HY) Lowest at USD 664.99 MM
  • DEBT-EQUITY RATIO (HY) Highest at -52.79 %
2
With ROE of 19.39%, it has a expensive valuation with a 11.40 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 61.08%, its profits have risen by 13.1% ; the PEG ratio of the company is 5.4
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Corcept Therapeutics, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Corcept Therapeutics, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Corcept Therapeutics, Inc.
-30.04%
1.29
121.85%
S&P 500
13.66%
0.81
19.85%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
15.31%
EBIT Growth (5y)
-6.28%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
1.01
Tax Ratio
1.56%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
83.87%
ROCE (avg)
111.37%
ROE (avg)
21.09%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
59
Industry P/E
Price to Book Value
11.40
EV to EBIT
67.34
EV to EBITDA
66.34
EV to Capital Employed
20.65
EV to Sales
10.89
PEG Ratio
5.37
Dividend Yield
NA
ROCE (Latest)
30.67%
ROE (Latest)
19.39%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 182.2 MM

RAW MATERIAL COST(Y)

Fallen by 0.24% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 1.13 times

NET SALES(Q)

Highest at USD 194.43 MM

-2What is not working for the Company
CASH AND EQV(HY)

Lowest at USD 664.99 MM

DEBT-EQUITY RATIO (HY)

Highest at -52.79 %

Here's what is working for Corcept Therapeutics, Inc.

Operating Cash Flow
Highest at USD 182.2 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales
Highest at USD 194.43 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Inventory Turnover Ratio
Highest at 1.13 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by 0.24% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Corcept Therapeutics, Inc.

Cash and Eqv
Lowest at USD 664.99 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio
Highest at -52.79 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio